Cantargia presents unique effects of nadunolimab in pancreatic cancer

Cantargia today presented new preclinical data for its lead candidate, the IL1RAP-binding antibody nadunolimab at the AACR Annual Meeting. The data show that nadunolimab targets a fundamental...

Related Keywords

California ,United States ,San Diego ,Nicholas Willumsen ,Lund University ,Nordic Bioscience ,